Does presence of complex translocations involving BCR::ABL1 in chronic myeloid leukemia affect the response rate to tyrosine kinase inhibitors? A systematic review of the literature
- 9 April 2024
- journal article
- review article
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 71, 152303
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Saudi Arabian CML patient with a novel four‐way translocation at t(9;22;5;2)(q34;q11.2;p13;q44)Molecular Genetics & Genomic Medicine, 2022
- Evaluation of cytogenetic response in CML patients with variant Philadelphia translocationAsia-Pacific Journal of Clinical Oncology, 2021
- Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR‐ABL1 transcript using Nanopore sequencingThe Journal of Gene Medicine, 2020
- Novel four-way Ph translocation t(9;22;7;1)(q34;q11;q22;p13) in a chronic myeloid leukemia patient receiving tyrosine kinase inhibitor therapyInternational Journal of Hematology, 2012
- Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid LeukemiaAdvances in Hematology, 2009
- Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case reportMolecular Cytogenetics, 2009
- Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosomeBritish Journal of Haematology, 2004
- Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyBlood, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- The biology of signal transduction inhibition: Basic science to novel therapiesSeminars in Oncology, 2001